Introduction
The mammalian prion protein (PrP) is a cell surface glycoprotein whose misfolding is associated with both the transmission and pathogenesis of a variety of neurodegenerative diseases (reviewed by Prusiner, 2001; Aguzzi and Haass, 2003) . These diseases, which include Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler-Scheinker (GSS) disease in humans, are characterized by a progressive spongiform degeneration of neurons accompanied in many cases by the deposition of PrP-containing aggregates in selected regions of the brain. In most, but not all instances of neurodegeneration associated with PrP, the disease is transmissible. The transmissible agent is predominantly composed of a misfolded conformer of PrP termed PrP Sc . While the identification of the transmissible agent and its mechanism of propagation have been the subjects of intense study, relatively little is understood about how changes in PrP folding and/or metabolism can lead to neuronal dysfunction and death.
Increasingly however, it is becoming clear that the accumulation of PrP Sc in the brain, while central to transmission of disease, may not directly cause neurodegeneration. For example, extensive deposition of PrP Sc in the context of neurons not actively expressing PrP does not lead to neuronal damage and death (Brandner et al, 1996; Mallucci et al, 2003) . Conversely, certain naturally occurring or artificially created mutations in PrP can lead directly to neurodegeneration without generating the transmissible PrP Sc form (Tateishi and Kitamoto, 1995; Tateishi et al, 1996; Hegde et al, 1998 . Thus, PrP Sc accumulation is neither uniformly necessary nor sufficient for neuronal toxicity. These and other findings have led to the idea that other facets of normal PrP metabolism may play critical roles in disease pathogenesis Chiesa and Harris, 2001; Hegde and Rane, 2003) .
Recent studies have begun to implicate events during the initial biogenesis, trafficking, and degradation of PrP at the endoplasmic reticulum (ER) in the development of neurodegeneration (reviewed in Hegde and Rane, 2003) . One neurotoxic form of PrP is a transmembrane isoform (termed Ctm PrP; Hegde et al, 1998) that is generated during the initial translocation of PrP into the ER . Although wild-type PrP generates relatively little (o10%) Ctm PrP in vivo, several mutations in the potential transmembrane domain significantly increase its generation (Hegde et al, 1998 Kim et al, 2001; . Expression of such Ctm PrP-favoring mutants in transgenic mice causes neurodegeneration (Hegde et al, 1998 , and at least three naturally occurring human mutations in the transmembrane domain result in increased Ctm PrP generation (Hegde et al, 1998; . Thus,
Ctm
PrP appears to play a direct role in at least a subset of PrP-mediated diseases, although the mechanism by which it causes cell death remains unknown.
More recently, it has been demonstrated that inappropriate expression of PrP in the cytosol can be both neurotoxic in mice and aggregation-prone in cells (Yedidia et al, 2001; . However, the pathways by which PrP would appear in the cytosol remain speculative and contentious Lindquist, 2001, 2002; Yedidia et al, 2001; Drisaldi et al, 2003; Hegde and Rane, 2003; Roucou et al, 2003) . In one model, a proportion of PrP is proposed to misfold in the ER lumen, be recognized by the ER quality control machinery, and subsequently be retrotranslocated to the cytosol for degradation by proteasomes Lindquist, 2001, 2002) . However, the observation that at least some of the PrP that accumulates upon proteasome inhibition contains an uncleaved signal peptide suggests that another route to the cytosol may involve a failure of PrP translocation into the ER (Drisaldi et al, 2003) . In either case, the role of cytosolic PrP in disease pathogenesis remains unclear, ranging from protective (Roucou et al, 2003) to toxic roles , having been proposed by different investigators.
Clearly, any putative roles for cytosolic PrP in normal physiology (Roucou et al, 2003) or disease pathogenesis (Yedidia et al, 2001; ) cannot be delineated without the ability to selectively modulate its generation. This requires an understanding of the pathway(s) by which proteins that are normally trafficked through the secretory pathway can reside in the cytosol. Like most secretory and membrane proteins (Rapoport et al, 1996) , PrP contains a signal sequence that mediates cotranslational targeting to and translocation across the ER membrane. The general efficiency of signal-mediated segregation to the ER, particularly in vivo is not well studied. However, in vitro studies have recently suggested that certain early steps in protein translocation across the ER may not be uniformly efficient for all substrates (Rutkowski et al, 2001; . In addition, in vivo analysis of the kinetics of signalmediated targeting (Johnsson and Varshavsky, 1994; Goder et al, 2000) and the steady-state presence of a signal-containing reporter in the cytosol (Levine et al, 2004) suggest that substrates differ in their efficiency of segregation into the ER. Presumably, the nontranslocated fraction of many such proteins would be viewed as undesirable in the cytosol, and need to be disposed by the ubiquitin-proteasome system. The physiological significance or relative contribution of such inefficiencies in ER protein translocation to the total substrate pool handled by cytosolic proteasomes in vivo has not been examined. In this study, we have analyzed this issue for PrP to reveal an unanticipated relationship between protein translocation, protein degradation, and the potential for PrP aggregation in the cytosol.
Results and discussion

Measurement of signal sequence efficiencies in vivo
A transcription factor (TF) sequestration assay (described in detail elsewhere (Levine et al, 2004) ; see also Supplementary Figure S1A ) was used to measure the in vivo efficiency of signal sequence-mediated protein segregation into the ER. Here, any inefficiency of a signal sequence to direct the TF into the ER is detected by activation of a cotransfected luciferase reporter. When TF lacking a signal sequence was tested, a dose-dependent increase in reporter activity is observed over a broad range of expression ( Figure 1A ), even at TF levels that are below the detection threshold for immunoblotting ( Figure 1B ). When TF was preceded by the PrP signal sequence (PrP-TF), reporter activity was reduced sharply (B10-20-fold) despite identical levels of TF expression ( Figure 1A and B). Quantitation relative to the standard curve of signal-less TF suggested that, depending on experimental conditions (e.g., growth state and confluency of the cells), between 5 and 15% of total PrP-TF at steady state (B15% in Figure 1C ) was available in the nucleo-cytoplasmic compartment for reporter activation. Even at very low expression levels in cells growing under optimal conditions, at least 5% of PrP-TF was not segregated into the ER.
When other signal sequences were used in the same assay, the percent of cytoplasmic TF could be substantially increased or decreased relative to PrP-TF (Levine et al, 2004) . This is consistent with in vitro observations demonstrating that signal sequences can vary broadly in their functions at early steps in substrate translocation (Rutkowski et both in vitro and in the TF sequestration assay (Levine et al, 2004; Figure 1C and D and Supplementary Figure S1B) , are those from either prolactin (Prl) or osteopontin (Opn). Both of these resulted in B50% lower reporter activity relative to PrP-TF at comparable and modest expression levels (Figure 1C and D) , indicating that even the highest efficiency signals still permit substantial and readily detectable levels of total TF to exist in a functional state in the nucleo-cytoplasmic compartment.
Consequence of signal sequence inefficiency for PrP metabolism
To explore the relevance of this small but readily detectable inefficiency in the activity of some signals, we turned our attention to native PrP. Modulating PrP translocation by replacement of its signal sequence with the more efficient Opn or Prl signal sequences (termed Opn-PrP and Prl-PrP, respectively) did not lead to obvious changes in several properties of PrP when examined at steady state in unperturbed cultured cells: the glycosylation pattern, resistance to endoglycosidase H digestion, subcellular localization, solubility in nonionic detergents, surface expression, protease sensitivity, and site of signal sequence cleavage were all indistinguishable between these constructs (Figure 2B and Supplementary Figures S2, S3 and S4 and unpublished results) . When analyzed by pulse-chase studies, however, small differences could be detected in the metabolism of these three constructs ( Figure 2A ). Whereas B20% of PrP was observed to be unglycosylated after a brief 15 min pulse labeling, substantially less of this population was observed for Opn-PrP and Prl-PrP. By contrast, more than 50% of the synthesized PrP was unglycosylated when the less efficient angiotensinogen (Ang) signal sequence was used. The unglycosylated species of PrP for each construct was observed to be largely degraded within the 1-h chase period, a process that was retarded by proteasome inhibitors (Figure 2A ). During this same time frame, the glycosylated PrP was trafficked to post-ER compartments, as evidenced by its decreased mobility due to Golgi-specific carbohydrate modifications. Thus, in the absence of proteasome inhibition, the pattern of PrP isoforms within 1 h after a pulse labeling is very similar between the wild-type, Opn-PrP, and Prl-PrP constructs ( Figure 2A , top panel), consistent with their identical distributions at steady state. With proteasome inhibition, however, clear differences are observed in the amount of nonglycosylated PrP generated by differences in signal sequence efficiencies ( Figure 2A, bottom panel) .
The consequences of this nontranslocated population were explored further by determining the effects of prolonged proteasome inhibition. A concentration of proteasome inhibitor that only partially impairs the proteasome system (Supplementary Figure S5 ) was used to mimic the reduced degradative capacity thought to develop during the pathogenesis of various neurodegenerative diseases (Bence et al, 2001; Ciechanover and Brundin, 2003) or even the normal aging process (Gray et al, 2003) . With PrP, proteasome impairment with any of three different inhibitors results in the gradual accumulation of nonglycosylated PrP that is resistant to solubilization with mild detergents ( Figure 2B and Supplementary Figures S6 and S7A) . Remarkably, the generation of this insoluble nonglycosylated form was effectively abolished with Opn-PrP or Prl-PrP ( Figure 2B and Supplementary Figure S7A) , even upon prolonged inhibition of the proteasome (for up to 8 h; Figure 3A) .
Furthermore, small amounts of cytosolic PrP generated upon transient treatment with proteasome inhibitors have been reported to accumulate substantially over time by 'selfpropagation' . Although the mechanism of 'propagation' is not yet clear, this treatment protocol allows the detection of very small amounts of P C P C P C P C 
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Pel. Sup. Pel. cytosolic PrP, which presumably serves as a seed for subsequent accumulation. Under such propagation conditions that cause nearly all of the cellular PrP to become cytosolic, very little Opn-PrP accumulated in the unglycosylated form ( Figure 3B ). Thus, modulating PrP translocation by using a more efficient signal sequence can substantially reduce or even eliminate the ability of PrP to form nonglycosylated cytosolic aggregates under a variety of conditions. The consequences of modulating PrP translocation were also examined in live cells expressing wild type and/or OpnPrP tagged with different color variants (either cyan or yellow) of monomerized green fluorescent protein (mGFP). Co-expression of these two constructs in cultured cells demonstrated them to have the same localization as both each other and nontagged PrP ( Figure 4A and Supplementary Figure S2) , with the majority of PrP being found on the cell surface and lesser amounts in an intracellular pool colocalizing with the Golgi and endosomal compartments (unpub- Figure 2B ). (B) Effect of signal sequence on 'propagation' of cytoplasmic PrP aggregates. Two parallel plates each of N2a cells transfected with either wild-type PrP or Opn-PrP were treated for 2 h with 5 mM MG132. One plate (left panel) was harvested immediately and analyzed for PrP detergent solubility and aggregation. The second set of dishes was rinsed to remove the MG132, and incubated an additional 21 h in normal media (right panel) before harvesting for analysis of PrP detergent solubility and aggregation. After a 2 h 'pulse' of MG132, note that the immunoblots of PrP and Opn-PrP are largely indistinguishable: both show nearly quantitative solubility and little unglycosylated, insoluble PrP. After a 21 h chase, wildtype PrP was nearly all unglycosylated and insoluble, as has been proposed to occur by a 'self-propagation' mechanism . Even under these conditions, however, relatively little Opn-PrP was found in the unglycosylated, insoluble form. When examined in the same cell, a difference in PrP-mYFP and Opn-PrP-mCFP localization upon proteasome inhibition was readily apparent within 2-4 h ( Figure 4D ). Opn-PrPmCFP, similar to before proteasome inhibition (compare to Figure 4A ), continued to show localization at the cell surface and perinuclear structures. By contrast, PrP-mYFP now clearly showed additional accumulations in the cytoplasm that did not colocalize with Opn-PrP-mCFP ( Figure 4D ). At longer times after proteasome inhibition, this differential localization was more difficult to see, apparently due to substantial changes in cellular morphology caused by the accumulating PrP-mYFP (unpublished results). That notwithstanding, the ability to observe a difference in the localization for a population of PrP distinct from Opn-PrP within the same cell directly demonstrates that the trafficking pathways diverge for a discrete proportion of these two proteins. Hence, the differential consequences of the PrP and Opn signals on substrate translocation can be directly visualized in live cells during conditions of a compromised proteasome.
Colocalization studies showed that, both before and after proteasome inhibitor treatment, the majority of Opn-PrPmYFP was at the cell surface and in perinuclear structures consistent with Golgi and endosomes ( Figure 5A and B and Supplementary Figure S8) . By contrast, a significant proportion of the PrP-mYFP that accumulates after proteasome inhibition is found in cytoplasmic regions that do not colocalize with either Golgi or endosomes ( Figure 5D and Supplementary Figure 
Generation of cytosolic PrP independently of expression level
The single-cell analysis of PrP localization ( Figure 4C ) revealed that, even at relatively low levels of expression, a difference between PrP and Opn-PrP could be observed. This suggests that the basis of cytosolic PrP generation is not likely to be a consequence of saturating the ER targeting and translocation machinery. This conclusion was confirmed in two ways. First, we demonstrated that gross overexpression of Prl-PrP B5-10 fold above wild-type PrP still did not generate the aggregated nonglycosylated form of PrP upon proteasome inhibition ( Figure 6A and B). Thus, generation of unglycosylated PrP cannot be induced simply as a consequence of overexpression if a sufficiently efficient signal sequence is used for translocation. This indicates that even very high amounts of PrP in the ER lumen are insufficient to result in the generation of unglycosylated PrP by retrotranslocation.
In a second approach, we were able to observe the accumulation of nonglycosylated aggregates of the endogenously expressed PrP in nontransfected N2a cells treated with proteasome inhibitors ( Figure 6C ). Thus, the progressive generation and accumulation of insoluble, unglycosylated PrP upon proteasome inhibition is not a consequence of exogenous overexpression or the use of a viral promoter, as has been suggested previously (Drisaldi et al, 2003) . Many of the conclusions from these previous studies rested on the assumption that cytoplasmic, unglycosylated PrP would necessarily contain an uncleaved signal sequence if it were generated by aborted translocation. However, our previous studies indicate that the step at which some signals are inefficient in initiating translocation involves a post-targeting interaction with the Sec61-translocon . As the signal peptidase complex is at the translocon and removes signals cotranslationally (Rapoport et al, 1996) , the absence of the signal peptide may not necessarily be a reliable indicator of a protein having been completely translocated into the ER lumen. Examples of cytosolic localization after signal sequence cleavage of aborted translocation intermediates have been described previously (Garcia et al, 1988; Ou et al, 1989; Ooi and Weiss, 1992) . Indeed, we have found that, in vitro, cytoplasmic PrP containing a cleaved signal can be generated by chains that were targeted to, but only partially translocated through the translocon before completing synthesis in the cytosol (unpublished results). Consistent with this observation, we often see two unglycosylated species of PrP, separated by approximately the size of the PrP signal peptide, that accumulate to varying degrees in proteasome inhibited cells (e.g., see Supplementary Figure S6 ). Thus, the use of an anti-signal peptide antibody (Drisaldi et al, 2003; Stewart and Harris, 2003) as a sole marker for cytoplasmic PrP is unreliable, calling into question the interpretation of negative results that failed to detect signal-containing PrP in primary neurons or diseased brain . Conversely, the conclusion (Ma and Lindquist, 2001) , based solely on migration in SDS-PAGE, that PrP has been completely in the ER lumen (and was subsequently retrotranslocated) is potentially premature. Our observation that all forms of unglycosylated PrP (whether they are signal cleaved or not) are abolished by improving translocation into the ER lumen with the Prl or Opn signals indicates that little, if any, of the unglycosylated PrP is generated from chains that retrotranslocated from the lumen (since fully translocated chains are also made in abundance with Prl-PrP and Opn-PrP). Thus, considered together with Figure 1 , these results argue that a substantial proportion of the proteasomal burden of PrP is derived from an inherent inefficiency in its signal sequencemediated translocation into the ER.
Generation of cytosolic PrP in the absence of Ctm PrP
As discussed in the Introduction, the Ctm PrP transmembrane form, similar to cytosolic PrP, causes neurodegeneration if overexpressed in transgenic mice. In the brains of Ctm PrPexpressing mice, the PrP is almost exclusively found in post-ER compartments, suggesting that Ctm PrP passes the quality control machinery of the ER and exits to the Golgi (Hegde et al, 1998) . Recently, however, the overexpression of a signal sequence and transmembrane domain double mutant of PrP (termed L9R/3AV) that is made predominantly in the Ctm PrP form was shown to be degraded by proteasomes . Whether the behavior of this mutant reflects the properties of Ctm PrP generated by wild-type PrP is not yet clear. However, this observation, although at odds with the findings in brain, suggests that Ctm PrP could be a precursor to cytosolic PrP. Such a model would also be consistent with the finding that, in vitro, the generation of Ctm PrP depends in part on a slightly inefficient signal sequence (Kim et al, 2001 .
To test this possibility, we analyzed the behavior of PrP constructs containing mutations in the transmembrane domain that either increase or abolish the ability to generate N2a cells were transfected with either wild-type PrP or a larger amount of Prl-PrP. In both cases, equal amounts of a plasmid expressing GFP were cotransfected. A fixed amount of cell lysate from PrP-expressing cells (1 Â ; lane 2) was compared to different amounts of cell lysate from the Prl-PrP-expressing cells (from 0.1 Â to 1 Â ; lanes 3-6). Cells transfected with just GFP (nt; lane 1) are also shown as a control. Immunoblots were probed with antibodies against PrP, GFP, and an endogenous protein, the beta subunit of Sec61. Note that GFP and Sec61 levels are comparable when equal amounts of nt, PrP, and Prl-PrP cell lysates are compared (lanes 1-3). By contrast, Prl-PrP is expressed at B5-10-fold higher levels than PrP, as indicated by the observation that equal intensities are observed when 0.1-0.2 Â of Prl-PrP (lanes 5 and 6) is compared to 1 Â of PrP (lane 2). (B) Duplicate dishes of cells from lanes 1 and 2 of panel A were either left untreated or treated for 4 h with 5 mM MG132 prior to harvesting and fractionation of detergent-soluble PrP (Sup.) from insoluble PrP (Pel.). One-tenth the amount of PrlPrP lysate was analyzed on the gel to allow direct comparisons between the samples. Note that, with PrP, unglycosylated, insoluble PrP (U) is generated upon MG132 treatment. However, despite the B10 Â overexpression of Prl-PrP, this form is not generated. (C) Effect of proteasome inhibition on endogenously expressed PrP. Untransfected N2a cells were treated for between 0 and 8 h with 5 mM MG132 before analysis of total proteins by immunoblotting with the 7D9 anti-PrP antibody (which detects mouse PrP). Note that an unglycosylated species of PrP (U) accumulates over 8 h (left panel). Samples from the 8 h treatment were also analyzed for PrP detergent solubility and aggregation (right panel). Note that a substantial fraction of the unglycosylated PrP is in the detergent insoluble pellet (P), while all of the mature, glycosylated PrP (M) is in the detergent-soluble supernatant (S). inhibition ( Figure 7B and Supplementary Figure S7B) . Furthermore, mutants which increase Ctm PrP generation (such as PrP(A117V) and PrP(AV3); see Hegde et al, 1998) also did not influence the generation of nonglycosylated cytosolic PrP aggregates upon proteasome inhibition ( Figure 7B and Supplementary Figure S7B) . Importantly, we confirmed that, in the N2a cells used for these studies, the PrP(AV3) and PrP(G123P) mutants increase and abolish, respectively, the generation of Ctm PrP ( Figure 7A and Supplementary Figure S10) , exactly as observed in vitro and in mouse brain (Hegde et al, 1998) . Thus, while Ctm PrP and cytosolic PrP appear to share some common features (such as their potential toxicity, exposure to the cytosol, and dependence on an inefficient signal sequence for generation), they do not appear to have a precursor-product relationship. Instead, cytosolic PrP can be generated largely independently of whether Ctm PrP is made or not. This further suggests that the majority of cytosolic PrP is not generated by PrP molecules that are first inserted into the ER, regardless of their topologic form.
Consequences of signal sequence efficiency for susceptibility to cell death
Recent studies have demonstrated that, when inappropriately expressed in the cytosol, PrP is not only susceptible to aggregation, but is selectively toxic to a subset of cells (primarily of neuronal origin), both in culture and in a transgenic mouse model . We therefore asked whether modulation of PrP translocation into the ER could at least partially alleviate the sensitivity of PrP-expressing cells to the cytotoxic consequences of decreased proteasome activity. Remarkably, as assessed by either Annexin V exposure on the extracellular surface ( Figure 8A and B) or overall cell viability ( Figure 8C ), cells expressing Opn-PrP tolerated partial proteasome inhibition considerably better than cells expressing PrP. In fact, overexpression of Opn-PrP had no detectable adverse consequence beyond that observed in cells expressing either no exogenous proteins or expressing unrelated secretory or cytoplasmic proteins.
These results suggest that removing the potential to generate cytosolic PrP by the pathway involving inefficient translocation is sufficient to eliminate the PrP-mediated susceptibility to proteasome inhibition. Thus, overexpression of PrP in the lumen of the ER (e.g., with Opn-PrP) does not increase the susceptibility of cells to proteasome inhibition beyond that observed in control cells. This argues that, at least under nonstressed steady-state conditions, translocation into the ER is the decisive step in avoiding the generation of cytotoxic forms of PrP that would ordinarily be degraded by the proteasome. Although these proteasomally degraded forms of PrP can lead to cell death under some circumstances (e.g., ; this study), the roles they play during the pathogenesis of either transmissible or genetic forms of prion disease remain unknown. The ability to eliminate (or at least substantially reduce) the generation of these forms of PrP in vivo should now allow the testing of currently controversial hypotheses proposing their involvement in disease pathogenesis.
Conclusions
The results presented in this study identify inefficiencies in signal sequence-mediated protein segregation to the ER as a major and previously unappreciated pathway for the generation of substrates to be degraded by the proteasome. This inefficiency appears to account for the majority of proteasomally degraded PrP. Importantly, reducing this nontranslocated population by improving signal sequence function reduces the proteasomal burden of cytosolic PrP. This allows cells to normally process PrP in the secretory pathway, while avoiding the generation of an insoluble, aggregated, and potentially cytotoxic population of cytoplasmic PrP even Untreated MG132 Sup.
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The inefficient translocation pathway for generating cytoplasmic PrP is not mutually exclusive of the previously proposed mechanism involving the cellular quality control machinery and retrotranslocation from the ER lumen (Yedidia et al, 2001; Lindquist, 2001, 2002; Cohen and Taraboulos, 2003) . However, with wild-type PrP in nonperturbed cells, the retrotranslocation pathway does not appear to contribute substantially, since the proteasomally degraded population of PrP could be effectively eliminated by improving its initial import into the ER. Furthermore, the B20% of nontranslocated PrP we have observed would appear to sufficiently account for the previous estimates (Yedidia et al, 2001 ) that B10% of total synthesized PrP is metabolized via the proteasome pathway. With mutations or conditions that promote PrP misfolding in the ER lumen, retrotranslocation to the cytosol may be an additional source of proteasomally degraded PrP Lindquist, 2001, 2002; Cohen and Taraboulos, 2003) . The relative contribution of such putative events to the total amount of proteasome substrate remains to be determined, but can now be evaluated with the identification of PrP variants that largely eliminate inefficient translocation as a source of proteasomal substrate.
Implications for other proteins
The observation of inefficient PrP translocation, together with the finding that the signal sequences of many proteins may be even less efficient than that from PrP Levine et al, 2004) , has implications for other disease processes that involve proteins trafficked through the secretory pathway. A particularly notable example may be Alzheimer's disease (AD), which involves at least two proteins, APP and ApoE, that contain signal sequences for ER translocation (Selkoe, 2001) . How these proteins contribute to cell death during the pathogenesis of AD continues to elude a unifying explanation (Selkoe, 2001; Kawasumi et al, 2002; Caughey and Lansbury, 2003) . However, for both APP and ApoE, recent studies have suggested that inappropriate mislocalization to the cytosol can have adverse consequences, some of which resemble the pathological events in AD (Huang et al, 2001; Anandatheerthavarada et al, 2003) . Indeed, the observation of ubiquitin-conjugated secretory or membrane proteins in plaques or deposits accumulating during both normal aging and certain neurodegenerative diseases (Gray et al, 2003; Lang-Rollin et al, 2003; Kang et al, 2004) suggests access of the cytoplasmic ubiquitination and degradation machinery to proteins normally trafficked through the secretory pathway. An initial analysis of the signal sequences from APP and ApoE in vitro revealed that they were similar or less efficient than the PrP signal in their function of initiating translocation through the translocon (unpublished results). Thus, it will be of interest to determine whether a substantial population of these proteins transiently traffics through the cytoplasm, and, if so, what role this has in the pathogenesis of disease.
Finally, the nontranslocated population of substrates containing signal sequences may not necessarily be targets for immediate degradation. If a protein can be made in two subcellular locales at varying efficiencies, it may be anticipated that, in at least some instances, both populations have functional roles in the cell. Indeed, proteins with functions in both the ER and the cytoplasm have been proposed , although a mechanism to explain their dual localization remains obscure. Consistent with such an idea, the relative inefficiencies in the signal sequences of many substrates, including PrP, are evolutionarily conserved . This is particularly puzzling in the case of PrP where, based on the present and previous studies, a cytoplasmic population would appear to be disadvantageous. However, other work suggesting that at least in some cells, a cytoplasmic form of PrP not only exists abundantly (Mironov et al, 2003) but also may be beneficial (Roucou et al, 2003) raises the intriguing idea that PrP has evolved to maintain a balance between multiple forms, all of which have functional roles in subsets of cells at particular times. How the abundances of these different forms are regulated and what their putative functions are remains to be determined. But this may explain why, despite the clear potential for adverse consequences, the inefficient signal sequence of PrP has not evolved to be as efficient as those from Opn or Prl.
Materials and methods
Cells, plasmids, and reagents MDCK and Neuro 2a (N2a) cells were obtained from the American Tissue Culture Collection (ATCC) and S Priola (NIH), respectively. Fluorescent protein expression plasmids were from Clonetech. The pLuc plasmid (luciferase reporter preceded by the Gal4 DNAbinding element) was from Stratagene. Plasmids for expression of TF-and PrP-containing constructs used the pCDNA vector (Invitrogen) and are described in detail in Supplementary data. Antibodies were obtained from: GFP (JL8; Clonetech); NF-kB (Santa Cruz Biotechnologies); mouse PrP (7D9; Signet Laboratories); hamster PrP (3F4; a gift from S Prusiner); beta-COP (a gift from J LippincottSchwartz); EEA1 (BD Transduction Laboratories); Cy3-and Cy5-conjugated secondary antibodies (Jackson ImmunoResearch). Proteasome inhibitors were from Calbiochem.
TF sequestration assay
MDCK cells in 96-well plates were transfected (using Lipofectamine from Invitrogen) with 160 ng pLuc, varying amounts of TFcontaining plasmid, and YFP plasmid to make a total of 200 ng DNA per well. After 18-24 h, cells were harvested for parallel luciferase measurements (using a Luciferase Reporter Kit from Roche) and immunoblotting. Between three and six independent replicates were used for luciferase measurements. The assay is characterized extensively elsewhere (Levine et al, 2004) with further details provided in Supplementary data.
Biochemical analyses
Experiments analyzing PrP constructs were performed between 18 and 24 h after transfection (using Lipofectamine 2000) of N2a cells. Pulse-chase experiments were performed in six-well dishes. Pulse labeling was for 15 min with 150 mCi/ml 35 S-Translabel (ICN), and chase was for 1 h with unlabeled media. Proteasome inhibition (5 mM MG132) was initiated 2 h prior to pulse labeling, and continued throughout the pulse and chase incubations. Cells were harvested and PrP was immunoprecipitated with the 3F4 antibody as described ; also see Supplementary data). Analysis of PrP solubility and aggregation was as reported previously Lindquist, 2001, 2002; Yedidia et al, 2001) and described in detail in Supplementary data. The assay for 'selfpropagation' of cytosolic PrP aggregates was performed as reported previously and described in the legend to Figure 3 . Detection of Ctm PrP used a previously published assay (Hegde et al, 1998 , and was performed on microsomes isolated from transfected cells as described in Supplementary data. All immunoblots were stained with Ponceau S to verify equal loading of samples (as shown in Figure 2B ).
Imaging and quantitative analyses
Fluorescence microscopy utilized an LSM510 confocal microscopy system (Zeiss). Imaging conditions, quantitative analyses of localization, double immunofluorescence, and colocalization studies were essentially as reported previously (Snapp et al, 2003 and references therein), with further details provided in Supplementary data.
Cytotoxicity analysis
Analysis of cell death using Cy5-labeled Annexin V was as recommended by the manufacturer (Molecular Probes). The amount of Annexin staining from three independent experiments was averaged to generate the graph in Figure 8B . Total cell viability ( Figure 8C ) was determined by trypan blue exclusion. Viable and nonviable cells were tabulated manually using a hemocytometer and the results of multiple independent experiments were averaged.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
1
Supplementary Methods
Plasmid Constructions
Expression plasmids in the pCDNA vector (Invitrogen) encoding wild-type hamster PrP, OpnPrP, Prl-PrP, and Ang-PrP have been described Rutkowski et al., 2001 ). The Opn, Prl, and Ang signals were from rat, bovine, and human sequences, respectively. Fusions to the PrP mature domain were blunt-ended and did not introduce any linker codons. The expression plasmid for TF (a heterologous Gal4-NFkB transcription factor) driven by a CMV promoter (plasmid pBD-NFkB) and the luciferase reporter plasmid preceded by the Gal4 DNAbinding element (plasmid pLuc) were obtained from Stratagene. To prepare the signal-TF constructs, the TF coding region was first amplified by PCR from plasmid pBD-NFkB and subcloned in frame into a calreticulin expression construct at the unique Not1 site just preceding the C-terminal KDEL ER retention sequence. Using this plasmid as a template, the region coding for TF, together with the KDEL sequence, was then PCR amplified and subcloned into a blunted Pst1 site and a downstream Xba1 site of cassettes containing different signal sequences. Such signal sequence cassettes have been described previously . Again, fusions between the signal and mature domains were blunt-ended and did not introduce any linker codons. The coding regions of PrP(G123P), PrP(AV3), and PrP(A117V) have been described (Hegde et al., 1998) . They were subcloned by standard methods into the pCDNA mammalian expression vector for use in this study. Point mutations to monomerize the CFP and YFP expression plasmids (obtained from Clonetech) were introduced as described previously (Snapp et al., 2003) by site-directed mutagenesis using the Quickchange method (Stratagene). PCR- 
Biochemical analyses
Pulse-chase studies. All experiments analyzing PrP constructs were performed in N2a cells cultured in DMEM containing 10% fetal bovine serum. After transfection with the appropriate plasmids (using Lipofectamine 2000), cells were analyzed between 18 and 24 hours later. Pulsechase experiments were performed in 6-well dishes on cells pre-incubated for 30 min in media lacking methionine and cysteine. Pulse labeling was for 15 min with methionine/cysteine-free media containing 150 uCi/ml 35 S-Translabel (ICN); chase was carried out with unlabeled complete media for 1 h. Proteasome inhibition (5 uM MG132) was initiated 2 h prior to pulse labeling, and continued throughout the pulse and chase incubations. At the time of harvesting, cells in each well were rinsed in PBS, solubilized in 100 ul of 1% SDS, 0.1M Tris, pH 8, denatured by boiling, diluted 10 fold in IP buffer (1% Triton X-100, 50 mM Hepes, pH 7.4, 100 mM NaCl), and immunoprecipitated with the 3F4 anti-PrP monoclonal antibody as described . Gels of the immunoprecipitates were always stained with Coomassie blue to verify equal recovery of the antibody complexes and equal loading prior to their drying and autoradiography.
PrP aggregation assay. Analysis of PrP solubility and aggregation was performed with minor modifications to previously published procedures (Yedidia et al., 2001; Ma and Lindquist, 2001; . Cells were cultured and transfected in 12-well dishes, and between 18-24 hours after transfection, treated with various manipulations as described in the individual figure legends. At the time of harvesting, cells in each well were washed once in PBS, scraped into 500 ul of ice cold solubilization buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate), dispersed by repeated pipetting, and centrifuged for 10
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min at 13,000 x g at 4°C. Proteins in the pellet were dissolved in 50 ul of 1% SDS, 0.1M Tris, pH 8. Proteins in the supernatant were precipitated on ice with trichloroacetic acid (added to 15% w/v), collected by centrifugation at 4° C for 2 min at maximum speed in a microcentrifuge, washed once in ice cold acetone, air dried, and dissolved in 50 ul of 1% SDS, 0.1M Tris, pH 8.
Equal aliquots of each fraction (usually 7.5 ul) were analyzed by SDS-PAGE and immunoblotting using 12% Tris-tricine minigels. All blots were stained for total protein with Ponceau S and confirmed to have equal loading in the lanes (as shown in Fig. 2B ). The treatment conditions for proteasome inhibition in each experiment are provided in the respective figure legends. The assay for 'self-propagation' of cytosolic PrP aggregates was performed as previously reported and described in the legend to Fig. 3 . Briefly, transfected cells were incubated for 2 hours in media containing 5 uM MG132 (a reversible proteasome inhibitor). After washing the cells in PBS, they were returned to normal media lacking MG132 and cultured for an additional 21 hours. Parallel cultures of cells were harvested after the initial MG132 treatment as well as after 'chase' in the absence of MG132, and processed for analysis of PrP solubility and aggregation as described above.
Assay for Ctm PrP in N2a cells. Detection of Ctm
PrP was performed on microsomes isolated from transfected cells in a 10 cm dish. Cells were first washed in PBS, scraped into ice cold hypotonic buffer (10 mM Tris, pH 7.4), disrupted by ~10 passes through a 25 gauge needle, and adjusted to 100 mM KAc, 2 mM MgCl 2 . Debris, unbroken cells, and nuclei were removed by centrifugation at 1,000 x g for 10 min at 4°C in a microcentrifuge. The supernatant was transferred to 1.3 ml ultracentrifuge micro-test tubes (Beckman) and centrifuged at 70,000 rpm in a TL100.3 rotor at 4° C to sediment the membranes. This crude membrane fraction was resuspended in 50 ul of 50
5
mM Hepes, pH 7.4, 100 mM KAc, 2 mM MgAc2, and 250 mM sucrose. Detection of Ctm PrP in these microsomes utilized the limited protease digestion assay described in Hegde et al. (1998) .
An aliquot of untreated microsomes were reserved for comparison. Samples after protease digestion were deglycosylated with PNGase F (New England Biolabs) prior to analysis by immunoblotting. In this assay,
Ctm
PrP is detected by its selective resistance to digestion under 'mild' conditions (1 h at 4°C with 0.25 mg/ml proteinase K and 1% Triton X-100) to generate a diagnostic 18 kD fragment (after removal of carbohydrates with PNGase). This fragment is lost upon digestion with 'harsh' conditions (1 h at 37°C with 0.1 mg/ml proteinase K, 0.5% Triton X-100, 0.5 % deoxycholate).
Imaging and quantitative analyses
Fluorescence microscopy of N2a cells utilized an LSM510 confocal microscopy system ( was used to derive relative expression levels (Snapp et al., 2003) . A correction factor (derived in independent measurements based on the change in detector gain settings) was used to allow Supplementary Materials, Rane et al.
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plotting of both bright and dim cells from the two imaging settings on the same graph. Percent surface localization was defined as the fraction of total fluorescence found in the outer rim of each cell. Although this systematically underestimates surface localization (because the top and bottom surfaces of cells are not included), it nonetheless allows relative comparisons to be made.
We determined the degree of underestimation to be roughly two-thirds the actual value based on independent experiments using protease digestion of cell surface PrP (which showed ~90% surface localization, compared to ~60-70% estimated by fluorescence). For immunofluorescence and co-localization studies, cells were grown on glass coverslips. At the time of analysis, they were fixed for 10 min at room temperature with 3.7% formaldehyde in PBS, rinsed twice with PBS, and permeabilized for 5 min with 0.5% Triton X-100 in PBS. After removing the permeabilization buffer, cells were incubated for 1 h at room temperature in blocking buffer (PBS containing 10% fetal bovine serum, 0.1% saponin, and 50 ug/ml RNAse A). Incubation with primary antibodies (mouse anti-EEA1 and rabbit anti-beta-COP) diluted into blocking buffer was for 1 hour at room temperature. After washing, cells were incubated for 30 min with Cy5-and Cy3-conjugated secondary antibodies (Jackson ImmunoResearch), washed with several changes of PBS, and mounted in Fluoromount (Molecular Probes) prior to imaging.
Cytotoxicity analysis
For Annexin V analysis, cells were co-transfected with GFP and the appropriate PrP plasmids. (A) Signal sequence-containing nascent polypeptides encoding a TF are co-translationally targeted to and translocated across the ER membrane (step 1), where they are retained by a C-terminal KDEL retention sequence. Inefficient targeting or translocation (step 2) results in cytosolic TF, where it is available to activate transcription of a luciferase reporter (step 3). Cytosolic TF could potentially also be generated if retrotranslocated TF escapes degradation (step 2a). TF is composed of a fusion between the Gal4 DNA binding domain and the transcriptional activation domain from NF-kB (plasmid pBD-NFkB from Stratagene). PrP-TF, Prl-TF, and Opn-TF were made by replacing the initiating methionine of TF with the appropriate signal sequence and appending a sequence encoding KDEL immediately preceeding the stop codon. The luciferase reporter (plasmid pFR-Luc from Stratagene) contains firefly luciferase preceeded by five Gal4 binding sites.
(B)
Comparison of luciferase activation by PrP-TF versus Prl-TF at various expression levels. Varying amounts of plasmid encoding PrP-TF and Prl-TF were co-transfected with a constant amount of pFR-Luc and the extent of luciferase reporter activation measured (RLU, relative light units; mean ± SD, n=5). Parallel samples were analyzed by immunoblotting with antibodies against NF-kB (bottom panel). Endogenous NF-kB (asterisk) serves as a loading control. Arrow indicates position of the exogenously transfected TF, which showed equal expression levels for PrP-TF and Prl-TF at each concentration of DNA used. At every level of expression, the Prl-TF consistently showed lower luciferase activity, indicating that it was segregated more efficiently into the ER than PrP-TF. The proportion of cytosolic TF contributed by retrotranslocation (step 2a) is not known, but can at most be the total seen with Prl-TF. Thus, the amount of cytosolic PrP-TF above this level represents the minimum amount that can be attributed to inefficient translocation (step 1). This suggests that for the PrP signal, at least one-third to one-half of all cytosolic TF must result from its inefficient translocation into the ER. Figure S4 -Analysis of the signal sequence cleavage sites of PrP, Opn-PrP, and Prl-PrP.
(A) Wild type PrP, Opn-PrP, and Prl-PrP were truncated at position 71 of the mature domain and synthesized in vitro (using rabbit reticulocyte lysate and ER-derived microsomal membranes from canine pancreas) using 35 S-methionine and 35 S-cysteine (exactly as in . On the left are the sequences of the three constructs, with the positions of the methionines and cysteines indicated in red. The predicted site of signal sequence cleavage is indicated by the large arrowhead. Note that the ONLY methionines and cysteines in each truncated construct are located in the signal sequence. On the right, note that only one radiolabeled product is observed, indicating that the signal sequence cleaved product does not contain any methionines or cysteines. Thus, cleavage must occur at a site after the last cysteine of each construct. That cleavage is indeed occurring can be demonstrated by parallel analysis (panel B) of constructs in which methionines are introduced into the mature domain (as indicated in red). Here, both signal uncleaved and signal cleaved products can be observed. Note that the signal cleaved products all migrate at the same position, while differences in migration can be seen for the uncleaved products. The difference in length between the Prl and PrP signal sequences is 8 residues (which can be clearly resolved), illustrating the resolution of these Tris-tricine gels in this size range. This means that the signal cleaved products for the three constructs (which migrate identically) cannot differ in size by more than 8 residues. Thus, cleavage at any alternative site for Opn-PrP and Prl-PrP must occur after the last cysteine in the signal, and at a site less than 8 residues from the predicted cleavage site. However, a comprehensive analysis of over 160 signal sequences (von Heijne, 1986, Nuc. Acid Res., 14:4683-4690 ) revealed that Proline is never found at the +1 or -3 positions (relative to the cleavage site), and that Lysine, Asparagine, Arginine, and Tryptophan are never found at positions -1 or -3. With these constraints, the only feasible alternative cleavage site downstream of the predicted site is 13 residues away (indicated by the small arrowhead). If Prl-PrP or Opn-PrP were being cleaved here, a size difference would have been seen; however, no difference is seen in the signal cleaved product under conditions where the size differences between the precursors of PrP, Prl-PrP, and Opn-PrP can be resolved (panel C). This demonstrates that in all three cases, cleavage is very likely to be occurring at the predicted site (indicated with the large arrow head). Cells transfected with wild-type PrP were treated for 6 hours with the indicated concentrations of the proteasome inhibitor MG132 prior to analysis by immunoblotting. DMSO indicates treatment with vehicle only. The positions of mature PrP (M) and unglycosylated PrP (U) are indicated. Note that upon proteasome inhibition, unglycosylated PrP accumulates, indicating that a proportion of total synthesized PrP is normally degraded by the ubiquitin-proteasome pathway (Yedidia et al., 2001; Ma and Lindquist, 2001) . Maximal inhibition was observed at concentrations above ~10 uM, while lower concentrations resulted in a partial inhibition. All other experiments in this study used 5 uM MG132 unless specifically stated otherwise.
Supplementary Material, Rane et al. Cells transfected with wild-type PrP were treated with 5 uM MG132 for between 0 to 8 hours prior to analysis by immunoblotting. Non-transfected cells are included as a control (nt). Lanes 12 and 13 show the detergent soluble supernatant (S) and insoluble pellet (P) after fractionation (Yedidia et al., 2001; Ma and Lindquist, 2001 ) of lysates from proteasome inhibitor-treated cells (4 hours with 5 uM). The positions of mature PrP (M) and unglycosylated PrP (U) are indicated. Note that in contrast to mature PrP, the unglycosylated PrP that accumulates with proteasome inhibition is largely insoluble, suggestive of its aggregation, as has been observed previously (Yedidia et al., 2001; Ma and Lindquist, 2001 ).
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S P S P S P S P U n t r e a t e d M G 1 3 2 L a c t a c y s t i n E p o x o m y c i n S P S P S P S P U n t r e a t e Cells transfected with various PrP constructs (indicated to the left of each blot) were treated with 5 uM of the indicated proteasome inhibitor for 4 hours prior to analysis of PrP by fractionation and immunoblotting. Non-transfected cells are included as a control ('non-trans.'). The detergent soluble supernatant (S) and insoluble pellet (P) after fractionation (Yedidia et al., 2001; Ma and Lindquist, 2001 ) of lysates from untreated or proteasome inhibitor-treated cells are shown for each construct. The positions of mature PrP (M) and unglycosylated PrP (U) are indicated. Note that in each case, treatment of wild type PrP results in the accumulation of detergent-insoluble, non-glycosylated PrP aggregates. This is markedly reduced by the use of a more efficient signal sequence (Opn-PrP), but not by mutations that either increase Ctm PrP production [e.g., the PrP(AV3) construct] or abolish Ctm PrP [e.g., the PrP(G123P) construct]. That Ctm PrP was in fact increased or abolished by these mutations was confirmed in these cells by independent experiments (Fig. 7A and Supplementary Fig. S10 ).
Opn-PrP-mYFP anti-EEA1 (Endosomes) anti-β-COP (Golgi) mYFP Merged image Figure S8 -Localization of Opn-PrP-mYFP after proteasome inhibitor treatment.
Cells were transfected with Opn-PrP-mYFP and treated with 5 uM MG132 for 4 hours prior to fixation and analysis by indirect immunofluorescence and confocal microscopy (exactly as in Fig. 5 ). Opn-PrP-mYFP was visualized directly, while endosomes and Golgi were visualized by staining with antibodies against EEA1 and β-COP, respectively. Shown are the individual channels and the merged image. Note that Opn-PrP-mYFP displays localization primarily at the cell surface and in perinuclear structures that colocalize partially with the Golgi, and partially with endosomal structures. This pattern is identical to that observed for Opn-PrPmYFP or wtPrP-mYFP before proteasome inhibitor treatment (see Fig. 4A , 5A, and 5C). By contrast, it is markedly different than the pattern observed for wtPrP-mYFP after proteasome inhibitor treatment (see Fig. 4D, 5D and Supplementary Fig. S9 ).
wtPrP-mYFP anti-EEA1 (Endosomes)
anti-β-cop (Golgi) mYFP Merged image Figure S9 -Localization of PrP-mYFP after proteasome inhibitor treatment.
Cells were transfected with PrP-mYFP and treated with 5 uM MG132 for 4 hours prior to fixation and analysis by indirect immunofluorescence and confocal microscopy (exactly as in Fig. 5 ). PrP-mYFP was visualized directly, while endosomes and Golgi were visualized by staining with antibodies against EEA1 and β-COP, respectively. Shown are the individual channels and the merged image. Note that PrP-mYFP displays enhanced intracellular localization relative to that seen prior to proteasome inhibitor treatment (e.g., compare to Fig. 4A and 5C ). While a proportion of this intracellular population co-localizes partially with Golgi and endosomal structures, a significant amount of it appears to be in cytoplasmic areas that are not occupied by either Golgi or endosomes. This pattern contrasts sharply with Opn-PrP-mYFP after a similar proteasome inhibitor treatment (see Fig. 4D , 5B, and Supplementary Fig. S8 ).
P r P P r P ( G 1 2 3 P ) P r P ( A V 3 ) n t P r P P r P ( G 1 2 3 P ) P r P ( A V 3 ) n t P r P P r P ( G 1 2 3 P ) P r P ( A V 3 ) n t Untreated Mild PK Harsh PK +PNGase +PNGase -Ctm PrP Figure S10 -Ctm PrP analysis of transmembrane domain mutants of PrP.
Shown is an overexposed blot of the experiment from Fig. 7A . This exposure illustrates the complete absence of Ctm PrP for the PrP(G123P) mutant (i.e., no diagnostic 18 kD band upon mild PK digestion). Note that on this exposure, the increase in Ctm PrP observed for the PrP(AV3) mutant (relative to wtPrP) is not readily appreciated as it is in the fainter exposure (Fig. 7A) . The minor bands seen for all three constructs in the 'mild PK' lanes of this overexposed blot may represent the very small proportion of PrP that is incompletely solubilized (and hence, inaccessible to protease digestion) under these conditions.
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